Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients

被引：0
|
作者：
Bjermer, Leif
van Boven, Job F. M.
Costa-Scharplatz, Madlaina
Gutzwiller, Florian S.
Lisspers, Karin
Mahon, Ronan
van der Molen, Thys
Olsson, Petter
Roche, Nicolas
Burke, Colin
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.PA939
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA939
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
    Bjermer, Leif
    van Boven, Job F. M.
    Costa-Scharplatz, Madlaina
    Keininger, Dorothy L.
    Gutzwiller, Florian S.
    Lisspers, Karin
    Mahon, Ronan
    Olsson, Petter
    Roche, Nicolas
    RESPIRATORY RESEARCH, 2017, 18
  • [2] Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
    Leif Bjermer
    Job F. M. van Boven
    Madlaina Costa-Scharplatz
    Dorothy L. Keininger
    Florian S. Gutzwiller
    Karin Lisspers
    Ronan Mahon
    Petter Olsson
    Nicolas Roche
    Respiratory Research, 18
  • [3] AN ECONOMIC EVALUATION OF INDACATEROL/GLYCOPYRRONIUM COMPARED WITH TIOTROPIUM AND SALMETEROL/FLUTICASONE FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THAILAND
    Boonsawat, W.
    Geater, S. L.
    Burke, C.
    Numuang, K.
    RESPIROLOGY, 2016, 21 : 180 - 180
  • [4] SAFETY OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) COMPARED WITH SALMETEROL/FLUTICASONE (SFC) IN MODERATE-TO-VERY SEVERE COPD PATIENTS WITH PRIOR EXACERBATIONS: RESULTS FROM THE FLAME STUDY
    Wedzicha, J.
    Vestbo, J.
    Larbig, M.
    Fogel, R.
    Thach, C.
    Patalano, F.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 181 - 181
  • [5] Delayed time to first and subsequent exacerbations independent of season with indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone (SFC): the FLAME study
    Chapman, Kenneth
    Kostikas, Konstantinos
    Olsson, Petter
    Thach, Chau
    Patalano, Francesco
    Fogel, Robert
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [6] Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
    Wedzicha, Jadwiga
    Chapman, Kenneth
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Olsson, Petter
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [7] EFFICACY OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) VERSUS SALMETEROL/FLUTICASONE (SFC) ON EXACERBATIONS AND HEALTH STATUS IN GOLD GROUP D COPD PATIENTS: THE FLAME STUDY
    Larbig, Michael
    Vogelmeier, Claus F.
    Roche, Nicolas
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Shrinivasan, Anupama
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    RESPIROLOGY, 2017, 22 : 131 - 131
  • [8] Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
    Larbig, Paul Michael
    Vogelmeier, Claus
    Roche, Nicolas
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Shrinivasan, Anupama
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [9] Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
    Roche, Nicolas
    Olsson, Petter
    Vestbo, Jorgen
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Clerkin, Karyn
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [10] COST-EFFECTIVENESS ANALYSIS OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) VS SALMETEROL/FLUTICASONE (SFC) AS MAINTENANCE TREATMENT FOR COPD PATIENTS IN TAIWAN: UPDATED BASED ON THE RESULTS OF THE FLAME STUDY
    Tan, E. C. H.
    Yang, M. C.
    VALUE IN HEALTH, 2019, 22 : S352 - S352
12345